OKLAHOMA CITY, OK — Contract Development and Manufacturing Organization (CDMO) Wheeler Bio and CRB — a global provider of sustainable engineering, architectural, construction, and consulting services to the life sciences industry — announce the start of construction on a GMP drug substance facility that will support innovators seeking agile, small batch manufacturing services for their clinical trial materials (CTM).

The 35,000-square-foot brownfield space is housed in the ultra-modern Ziggurat building located in downtown Oklahoma City. With closed processing and ballroom designs engineered by CRB and cleanroom construction partners, Lingo Construction Services, Inc., Wheeler is capitalizing on the latest innovations in cleanroom concepts allowing for agility that will better serve the needs of the early clinical phase developers.

"I am thrilled to announce the kickoff of our latest capital project to establish Wheeler's first GMP drug substance manufacturing capability in Oklahoma City," said Jesse McCool, CEO of Wheeler Bio. "The caliber of collaboration so far among stakeholders including Wheeler, CRB, and Lingo has been truly impressive, resulting in a detailed design that is a perfect reflection of our vision of an agile, phase appropriate, 'smart factory'."

"As the prominence of biologics grows in the global fight against viruses and disease, we're honored to work alongside Wheeler in providing flexible spaces that can support the continued evolution of this important work," said Ashley Reynolds, Market Team Leader of CRB.

Once complete, the facility will include ballroom GMP production suites, QC lab, GMP warehouse, and offices, providing Wheeler's customers with master cell banking, drug substance manufacturing, testing, and release services.